New conference: Translational cancer research - Integration of basic and clinical perspectives
We are excited to announce this excellent opportunity to connect with a vibrant community of scientists from both basic and clinical perspectives and to engage in meaningful discussions.
The Translational Cancer Research Conference will focus on integrating basic and clinical cancer research, exploring how to bridge the gaps between them, and presenting talks by leading international experts in basic and translational cancer research.
We hope to see you on 25 February 2026 at the Danish Architecture Centre in Copenhagen.
A no‑show fee of 925 DKK applies if a confirmed participant does not attend without prior cancellation.
Call for Abstracts: Now Open
We invite all interested researchers to submit abstracts on research projects, clinical trials or other research activities within the area of translational cancer research. Submitted abstracts can be considered for oral presentations – as talks of 10 minutes or speed talks of 4 minutes.
Your abstract should highlight the core aspects of your research in up to 300 words. The organizing committee will use the abstract to assess the relevance and quality of your submission. It should be clear, concise, and sufficiently detailed to stand on its own.
The text must include: Background, purpose, method, collaborators and results.
The abstract is submitted by a lead author on behalf of a group and the author list should therefore include both basic and clinical researchers.
Your abstract must be submitted to dccc.info@dccc.dk no later than 26 November, 2025 at 12 noon.
Abstracts will only be published for the conference participants.
Program
09:15 AM
Arrival and breakfast
09:45 AM
Welcome & Opening Keynote Speech
Targeting DNA Methylation in Cancer
Peter Jones, Distinguished Professor, PhD, DSc, Van Andel lnstitute
10:20 AM
Session 1: Integration of basic and clinical perspective
Moderators:
Signe Borgquist, Department Chair, Clinical Professor, Department of Oncology, Aarhus University Hospital and Clinical Medicine, Aarhus University
Linn Gillberg, Assistant Professor, Department of Biomedical Sciences, University of Copenhagen
- Epigenetics
Anja Groth, Professor, Group leader, Epigenome Replication and Maintenance, Danish Cancer Institute & Kirsten Grønbæk, Professor, Department of Haematology, Rigshospitalet - Rare cancers
Ninna Aggerholm Pedersen, Clinical Associate Professor, MD, Dep. Of Oncology, Aarhus University hospital/ Department of Clinical Research and Birgitte Sandfeld-Paulsen, MD PhD, Head of Department, Department of Clinical Biochemistry, Aalborg University Hospital - Renalcancer
Tommy Kjærgaard Nielsen, MD, PhD, Consultant, Head of Research, Clinical Associate Professor, Department of Renal and Urological Surgery, Aalborg University Hospital & Iben Lyskjær Heimann Associate Professor, PhD, Group leader, Department of Molecular Medicine, Aarhus University, MOMA - Mechanisms of cancer drug resistance
Henrik Ditzel, Professor, Head of Unit of Cancer Research, Department of Molecular Medicine, University of Southern Den mark, Head of Research, Department of Oncology, Odense University Hospital & Marianne Vogsen, MD, PhD, Associate professor, Department of Oncology, Odense University Hospital - Biologically guided radiation therapy
Mikael Palner, Associate Professor, Head of Preclinical lmaging Core Facility, University of Southern Den mark & Faisal Mahmood, Professor, Research unit of Oncology, Odense University Hospital and Department of Clinical Research - From Discovery to First-in-Human: Translating ADC Innovation into Clinical Trials
Lars Engelholm, Group Leader, Associate Professor, Finsen Laboratory, Rigshospitalet & Ulrik lassen, Group Leader, Professor, Department of Oncology, Rigshospitalet
12:20 AM
Lunch and networking
01:00 PM
Why DCCC has chosen to work with integration of basic and clinical cancer research
It is DCCC’s ambition to explore how the connection and integration between basic and clinical cancer research can be strengthened, and to support the implementation of more translational studies. It is essential that advances and breakthroughs in research – both in the laboratory and through new medicine and technological solutions – are translated into clinical practice.
To take the first steps, DCCC invites all researchers within the area of translational cancer research to a national conference focusing on the integration of basic and clinical cancer research. The ambition of the conference is also to take the first steps towards increasing visibility across the various local initiatives and translational cancer research environments. As the working language within translational cancer research is English, the conference will be conducted in English.
